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Abstract
Stanniocalcins are expressed in the pancreas tissue, and it was suggested a direct correlation between circulating insulin and STC2 concentra-
tions in human. Here, we show a significant correlation between STC1 and both glycaemia and glycosylated haemoglobin among DM2 patients,
while DM2 patients who present the greatest glycosylated haemoglobin values exhibited the lowest STC2 expression. However, treatment of
patients with antiglycaemic drugs does not significantly modify the expression of both STCs. On the other hand, STC2-/- mice that exhibited
neonatal and adult overweight further presented deregulated glycaemia when they were feed with a hypercaloric diet (breeding pellet, BP). This
alteration is more evident at the early stages of the animal life. Deregulated glycaemia in these mice was confirmed using glucose oral test. In
addition, STC2-/- mice present enhanced pancreas size; thus, the histological analysis reveals that WT mice respond to BP diet by increasing the
size of the pancreatic islets through inducing cell division, and STC2-/- mice lack this compensatory mechanism. Contrary, BP fed STC2-/- mice
show enhanced number of islets but of similar size than those fed with regular pellet. Histopathological analysis demonstrates tissue structure
disruption and erythrocytes infiltrations in STC2-/- mice, possibly due to the stress evoked by the BP diet. Finally, enhanced glucagon immunos-
taining was observed in the islet of STC2-/- mice, and the glucagon ELISA assay confirmed the increase in the circulating glucagon. Summariz-
ing, we present evidence of the role of STCs, mainly STC2, as a possible early marker during development of diabetes mellitus.
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Introduction
Stanniocalcins (STCs) were initially identified as a fish hormone that
regulates calcium and phosphate blood concentration [1]. STCs have
been described in human, but its physiological role remains unclear.
Nowadays, it has been identified the genes that codify for the human
homologues of fish STCs, but contrary to fish STC expression, in
mammals is much less localized, and as result, several tissues have
been reported as possible sources for mammal STCs [2, 3]. Nowa-
days, it has been established that STC1 gen is located within the short
arm of the chromosome 8, while STC2 gen was identified at the very
end of the long arm of chromosome 5. This different genetic profile,
together with the low structural similarity described for both STCs,
leads scientists to assume that both proteins may have completely
different functions. In fact, concerning their structures, while STC2
conserves around 10 histidine residues in the C-terminus domain that
allows metallic ions binding, STC1 seems to lack this domain [4].
Post-translational modifications of both proteins also differ; thus,
STC1 was described to be intracellularly phosphorylated by PKC,
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which regulates its function, but STC2 is targeted by the ectokinase,
casein kinase 2 (CK-2), in a not well-defined process that might leads
to STC2 secretion [5]. Regarding it function, STC1 regulates mineral
metabolism and intestinal calcium uptake in mammals, in a similar
function to the one described in fish [6]. However, there is scarce
information about the STC2 physiology, but some authors have pro-
posed that STC2 might regulate intracellular calcium homoeostasis
[7], and also it would act as protective protein against reticular stress
[8, 9]. In this sense, the STC expression has been reported to be
altered in severe pathologies, such as oesophageal squamous cancer,
breast cancer and thyroid cancer among other types [10, 11]; there-
fore, to improve our knowledge regarding the physiology of these
proteins might help to tackle those illness.
On the other hand, STC expression was confirmed in the pancreas
tissue; in fact, STC1 was described to be expressed together with
insulin in the beta cells of the pancreas islets [12]. Furthermore,
exogenous STC2 expression in mice resulted in a strong positive stain
in the pancreas islets, and subsequent immunohistochemical analysis
revealed that STC2 colocalize with glucagon in the alpha cells; thus,
the authors inferred a possible role of STC2 in glucose homoeostasis
[4]. Very recently, STC1 was reported to down-regulate gluconeogen-
esis in different kidney cells in rat and fish, and then, it would partici-
pate in the overall circulating glucose in mammal [13].
Elevated glycaemia defines the diabetes mellitus (DM). Regarding
the causes underlying the appearance of diabetes, both physicians
and scientists agreed that there are confluence factors such as an
unhealthy diet [14, 15], obesity [16], environmental toxicity [17] and
other factors related to the lifestyle [18]. Glycosylated haemoglobin
has risen as the method of election to diagnose DM2, according to
WHO, and thus, over 6% of glycosylated haemoglobin would charac-
terize a DM2 patient (World Health Organization, Geneva, 1999.
Report Number: WHO/NCD/NCS/99.2.). However, at this stage, when
alteration of haemoglobin becomes evident due to protein undergo
glycosylation, probably other proteins within the tissues may have
already been glycosylated, leading to tissue damage and dysfunction
[19]. Therefore, early diagnosis and characterization are fundamental
for preventing the tissue damage, and the identification of new early
genetic and proteomic markers that help shortening the establish-
ment of the appropriate therapy would be relevant for handle this ill-
ness. Herein, using a STC2-/- mice that present enhanced post-natal
growth, then it can be also consider as an obesity murine model, we
present evidence of a role of STC2 in the development of hypergly-
caemia associated with a high-fat food intake.
Materials and methods
Materials
Harlan Teklad 2014 and Harlan Teklad 2018 pellets were supplied by
ENVIGO(R) (Valencia, Spain), GLUCOCARDTM G+ meter, ARKRAY Factory
Inc. (Shiga, Japan). Human insulin (actrapid) was supplied by Novo Nor-
disk(R) (Bagsværd, Denmark). Mice food was purchased from Harlam
(ENVIGO)(Barcelona, Spain). Anti-STC1 and anti-STC-2 antibodies were
from Sigma-Aldrich(R) (Madrid, Spain). Peroxidase-conjugated affiniPure
goat antimouse and peroxidase-conjugated affiniPure donkey anti-rabbit
IgGs secondary antibodies were supplied by Jackson ImmunoResearch
Ltd.. Glucagon ELISA kit and antiglucagon antibody was purchased from
R&D systems (Cat. number DGCG0, Abingdon, UK). FITC-conjugated sec-
ondary antibody was from Santa Cruz Biotechnology (Dallas,TX, USA).
Reactive of analytic grade was supplied by Sigma-Aldrich(R).
Animals
STC2-/- mice were kindly provided by Dr. Roger Reddel (Children’s
research institute, Australia), while C57BL/6J WT mice were purchased
from Harlan (ENVIGO). Both animal groups were maintained and repro-
duced at 25°C and 12-hrs light/dark photoperiod in the animal house of
the University of Extremadura. Animals were divided in two main groups
and were allowed free access to drink and food that consisted on either
regular diet [regular pellet (RP); maintenance diet Harlan Teklad 2014] or
enriched diet [breeding pellet (BP); breeding diet, Harlan Teklad 2018];
the breeding pellet consisted in a hypercaloric food; which results in an
excess of 0,9 kJ/g containing more protein and fat than RP (Table 1).
DM2 patients and healthy individuals
DM2 patients were selected of the patients that regularly attend to the Man-
uel Encinas’s health centre for routinely control of their diabetic condition;
Table 1 Pellet macronutrient composition and caloric content
according to Teklad (ENVIGO)
Teklad
Global 14%
Macronutient % Weight % Calories
Crude protein 14.3 20





Neutral detergent fibre 18
Ash 4.7
Teklad
Global 18% Macronutrient % Weight % Calories
Crude protein 18.6 24





Neutral detergent fibre 14.7
Ash 5.3
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meanwhile, healthy blood samples were provided by the Extremadura
County blood donation centre. Similar number of patients, of both genders,
was selected, and their age ranges from 33 to 70 years. All DM2 patients
were previously diagnosed due to elevated basal glucose and glycosylated
haemoglobin over 6% according to WHO definition. These patients are
under different hyperglycaemic medication, as result, some of them pre-
sented normoglycaemia and normal haemoglobin glycosylation at the
moment of the blood extraction, as confirmed by the biochemical analysis.
Blood extraction was performed by nurses of the Extremadura County health
Service that belong to the above-mentioned health centres and following the
ethical laws and upon informative acceptance of the patients.
Mice plasma parameters
Glycaemia—Circulating glucose concentration was determined using a
glucometer device (GLUCOCARDTM G+ meter, ARKRAY Factory Inc.)
following manufacturer’s materials and instructions. Blood was collected
from anaesthetized animals (using an isoflurane chamber) from vein of
the tail regularly at 8:00 PM, and twice a month.
Glucose oral test—It was performed as described by the Zhan P and
collaborators [20]. Briefly, 2 mg/g bodyweight was intraperitoneal
injected to isoflurane-anaesthetized mice. Animal starvation for 4 hrs
previously to glucose injection was enough to reach and determine
basal glycaemia. Upon glucose solution injection, mice glycaemia was
determined for 2 hrs, and values were determined as described above
and represented in mg/ml.
Insulin tolerance test—Following the indications of the National
Mouse Metabolic Phenotyping Center (Massachusetts, USA), one solely
insulin intraperitoneal injection (0.5 U/kg) was administered to WT and
STC2-/- mice that have been previously starved for 4 hrs. In order to
ascertain the glycaemia, and subsequently, to diagnose a possible insu-
lin resistance syndrome, we draw three small blood samples from the
animals during the following one and a half hour.
Circulating Glucagon test—Blood samples were drawn from the
retro-orbital plexus of isoflurane-anaesthetized WT and STC2-/- mice fed
with BP, using a heparinized capillary, which was approved by our insti-
tution bioethical committee. Previous to blood extraction, animals were
starved for 4 hrs as recommended in the protocol. Mice plasma poor
platelet samples were obtained by differential centrifugation, and they
were used for determining blood glucagon content according to manu-
facturer’s instruction and using the commercial ELISA kit from R&Dsys-
tems. Glucagon values are presented in ng/ml.
Histological and tissue analysis
Animals were killed under the effect of isoflurane, and several organs
(heart, pancreas, liver, brain) were surgically isolated and injected with
ice-cold 4% paraformaldehyde. Upon determination of the wet weight of
each organ, they were immediately derived to the Histology Unit of the
Department of Animal Medicine of the Faculty of Veterinary Sciences
(University of Extremadura), for establishing possible anatomical and
histological difference between mice subgroups. Fixed pancreas was
dehydrated in an ascending scale of alcohols and subsequently embed-
ded in paraffin. The 5-micrometre-thick sections were routinely stained
with haematoxylin–eosin for subsequent histological study.
Non-superimposed micrographs of each sample were made (409
magnification) using a microscope, obtaining about 1 cm2 study
surface. In each one, the number of islets, size of the islets and size
and number of cells (according to the presence of nucleus) were stud-
ied. The data obtained were expressed as unit of measure (mm2 or
lm2, depending on the case). These parameters were performed using
a microscope (Eclipse Ni, Nikon, Melville, NY, USA), camera (DS-Ri,
Nikon) and an image analysis program Nis-elements Br 4.30, Nikon.
Immunohistochemistry—Upon deparaffination and rehydration, mice
pancreas section was incubated for 30 min at room temperature with
blocking solution (5% BSA in Tris buffer saline medium) to avoid non-
specific binding of the primary antiglucagon antibody provided with the
ELISA kit. Primary antibody 1:250 was incubated overnight and upon
washing two times with fresh TBS, and FITC-conjugated secondary anti-
body was added to the sample for an additional hour. A second round
of washing with TBS was required previous to observation of the sam-
ples under an epifluorescence inverted microscope (Nikon Diaphot
T200). FITC fluorescence was observed using the 450 nm excitation
wavelength in to avoid interference with the emission spectra, as well
as to facilitate possible erythrocyte infiltration that would denote tissue
damage (erythrocyte haemoglobin autofluorecence peak at 415 nm).
Epifluorescent images were acquired using a cooled digital CCD camera
(Hisca CCD C-6790, Hamamatsu, Japan) and 409 magnification.
Western blotting
Blood samples drawn from the healthy individuals, and DM2 patients were
processed as described elsewhere [21, 22]. Poor platelet plasmas and pla-
telets were isolated by differential centrifugation; subsequently, the samples
were fixed and lysed using Laemmli’s buffer containing the reducing agent
dithiotreitol (5% final concentration). Once all patient blood samples were
collected, the proteins were isolated by 15% SDS-page and subsequent
Western blotting was performed using monoclonal anti-STC1 and anti-
STC2 antibodies (incubated for 1 hr at 1:1000 in TBST supplemented with
5% of BSA). Upon incubating with the adequate secondary antibody, the
amount of both proteins was detected using a C-digit device from LICOR.
Analysis of the difference between samples was performed using ImageJ
free software from NIH. Additionally, reproving of the membranes with
anti–actin antibody was carried out as loading control.
Statistical analysis
Student’s t-test was used for confirming statistical differences among the
studied groups. Analysis of the variance was subsequently assessed by per-
forming Dunn’s and Tukey’s post-test for multiple comparisons. Further-
more, we have additionally performed Pearson’s correlation tests for
establishing possible links between different biochemical and demographic
parameters observed in the human DM2 patients. Data resulting a P < 0.05
are considered as significant, and also, only those parameters that presented
a correlation statistically significant are presented in the Results section.
Results
Altered STC2 expression in DM2 patients
Human platelets were used to analyse the expression of STCs in
human, and platelets have often been used as sentinel cells in the
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study of certain diseases such as Alzheimer and cancer [23, 24]. As
demonstrated in Figure 1A, platelets isolated from DM2 patients
exhibited a significant reduction of 27.0  7.0% in the STC2 expres-
sion, but not in STC1 expression (92.0  30.0%) compared to those
from healthy individuals, then revealing a possible relationship
between STC2 and glycaemia in human.
By comparing several variables of the DM2 patients, we have con-
firmed the existence of a very positive correlation between circulating
glucose concentration and glycosylated haemoglobin in these
patients, in agreement with previous publications (Fig. 1B). In addi-
tion, a positive correlation was found between STC1 and glucose
concentration, as well as between STC1 and glycosylated haemoglo-
bin (See Fig. 1C and D, respectively), but regarding the latest, no sig-
nificant differences could be stablished as compared to healthy
values (Fig. 1E). Contrary, as previously demonstrated by Moore
(Emma E. Moore, Gary Rosenberg, Angela Thostrud, David S. Weigle,
Hong Ping Renas, results patented under the Reference number:
WWO2001008697 A2), our results showed no direct correlation
between STC2 and glycaemia in DM2 patients (data not shown). How-
ever, when patients were grouped according to the glycosylated hae-
moglobin values, we find out that in the DM2 patients who presented
the highest glycosylated haemoglobin values (HbAc1 over 7), also
Fig. 1 Expression of STCs in platelets
drawn from healthy subject and DM2
patients. Platelets isolated from the blood
of either healthy individual or DM2
patients were fixed by mixing with
Laemmli’s buffer under reducing condition
(5% final DTT). Subsequent Western blot-
ting was carried out using specific mono-
clonal anti-STC1 and STC2 antibodies
according to the manufacturer’s recom-
mended protocol. Membranes were
reprobed with an anti–actin antibody for
protein loading control. Bar graphs repre-
sent fold increase of STC expression
respect STCs found in healthy individuals.
Data are representative of the three inde-
pendent experiments using up to 50 DM2
patients and 12 healthy individuals. (B–E)
Biochemical variables of DM2 patients
were analysed to establish statistical cor-
relation using the Pearson’s test. Only
those correlations that reached significant
values are shown. (F) Bar graphs show
the regulation of STC expression by differ-
ent antihyperglycaemic drugs. *, **, ***:
represent P < 0.05, P < 0.01 and
P < 0.001 as compared to the protein
expression found in healthy individuals, as
resulted from Student’s t-test and Dunn’s
post-test for histograms E and F, while
Pearson’s correlation was used in B-D.
ª 2017 The Authors.
Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.
687
J. Cell. Mol. Med. Vol 22, No 1, 2018
presented the lower STC2 expression as compared with the ones
found in healthy individuals (Fig. 1E). Interestingly, in the DM2 popu-
lation analysed, the antiglycaemic medication was unable to signifi-
cantly modify the expression rate of both STCs; however, the lowest
expression of STC2 was found in patients medicated with analogues
of GLP-1, which might be indicative of an alteration in the glucagon
mechanism (Fig. 1F).
Glycaemia in WT and STC2-/- mice
To ascertain whether STC2 is involved in the regulation of circulating
glucose, we have selected C57BL/6 mice both WT and STC2-/-. This
mice strain has been used in different studies related to glucose
metabolisms and could be a suitable animal model of diabetes melli-
tus [25]. Thus, preliminary analysis of general glycaemia from WT
and STC2-/- mice fed with regular pellet (RP) did not report statistical
difference among groups (Fig. 2A and B black traces and see also the
histogram D). Previous manuscripts reported an elevated predisposi-
tion within the obese population for suffering DM2 [26–31], which
agree with the fact that most of the patients selected for this study
were also overweight (50% of analysed patients have a BMI over 30),
and in addition, STC2-/- mice are oversize and overweight [32], as it
was corroborated in our colonies (reporting a weight of 20.0  1.9
gr and 26.7  1.72 gr in WT and STC2-/-, respectively, at the
10 weeks of age; n = 15–20; meanwhile at the age of 40 weeks, no
Fig. 2 General glycaemia in WT and
STC2-/- mice according to the type of diet.
(A–B) Graphs represent the glycaemia of
C57BL/6 WT (12 animals) and STC2-/-
mice (12 animals) analysed according to
the type of diet, either regular pellet (Tek-
lad global 2014) or breeding pellet (Teklad
global 2018). (C) Bar graphs represent the
mean glucose concentration during their
entire life. (D) Bar graphs represent mean
glucose concentration among the type of
diet used; n.s.: non-significant. *,**,
***represent a P < 0.05, P < 0.01 and
P < 0.001, as compared to animals fed
with the regular pellet diet; meanwhile, $$
$represents that P < 0.001 as compared
to glucose values found in WT fed with
Regular pellet. Statistical significance was
assessed using Student’s t-test (A–C) and
Tukey’s post-test in A, B and D.
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differences in weight were observed). Hence, we suggested whether
STC2-/- mice would be a good model for describing the molecular
events contributing with the appearance of DM2 in obese patients.
Furthermore, animals of both groups were fed with either regular pel-
let [RP, 2014 Teklad global 14% protein rodent maintenance diets
from Harlan (ENVIGO)] or breeding pellet (BP, 2018 Teklad global
18% protein rodent diet). Mice were maintained under normal pho-
toperiod and free access to food and drink. Animals were anaes-
thetized and blood samples were collected from the vein of the tail
twice a month, as described under Materials and Methods Section. As
demonstrated in Figure 2A (grey trace), STC2-/- mice exhibited a sig-
nificant higher concentration of blood glucose (these mice presented
a mean glucose of 149.7  5.0 mg/ml when fed with BP versus
128.6  3.9 mg/ml when are fed with RP. P < 0.05; See histogram
D in Fig. 2), which is particularly evident until the age of 65 weeks.
Upon 65 months, STC2-/- feed with both type of food presented simi-
lar glycaemia, perhaps due to the genetic predisposition of these mice
strains that are often used for obesity and diabetes mellitus murine
model. These results would explain the fact that a statistical difference
in the general glycaemia is observed between WT and STC2-/- mice if
data are analysed without considering the type of food use for feeding
them (Fig. 2, Histogram C). According to these results, STC2-/- mice
would represent a good experimental model of hyperglycaemia
induced by a hypercaloric diet, and then it could be used as experi-
mental model for establishing possible links between obesity and
DM2 appearance.
Fig. 3 Pancreas size and morphologic
changes in the pancreas of WT and
STC2-/- mice according to the type of diet.
WT and STC2-/- mice were fed with regu-
lar (RP) or hypercaloric breeding diets
(BP), and at the age of 40 week, animals
were killed (n = 4–6 of each group), and
subsequent surgical proceed was per-
formed for extracting the pancreas. Pan-
creas was immediately fixed in 4%
paraformaldehyde, after which, wet pan-
creas weight was estimated using an ana-
lytical balance digital precision electronic
scale. (A) Bar graphs represent either gen-
eral ratio of the wet pancreas weight
respect to the bodyweight. ***represents
P < 0.001 respect to the ratio of pan-
creas/bodyweight in WT mice. (B) Histo-
logical fixation and staining was
performed as described under Materials
and Methods, and subsequent histological
and cellular analysis was performed using
the software Nis-elements Br 4.30,
Nikon. **, ***represent P < 0.01 and
P < 0.001, as compared to the values
found in WT mice feed with regular pellet
(Teklad global 2014). $: P < 0.05 as com-
pared to the values found in the STC2-/-
mice fed with regular pellet; Student’s t-
test (A) and Dunn’s and Tukey’s test was
used (B).
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As shown in the Fig. S1, hyperglycaemic condition of the STC2-/-
mice fed with BP was further corroborated by performing the oral glu-
cose test; however, this strain does not present insulin resistance
according to insulin tolerance test that is also presented in the
Fig. S1B. So, hypercaloric diet would evoke pancreatic tissue alter-
ation mainly in STC2-/- mice that lead to deregulated insulin produc-
tion but not insulin action in the tissues.
Histological alterations in the STC2-/- mice
pancreas
To delve in the possible alteration evoked by a hypercaloric diet, mice
within the range of 40 weeks of age were selected for performing the
histological study. Upon determination of their bodyweight, animals
were killed as described in the Materials and Methods. Isolated pan-
creas was weighed and fixed in ice-cold paraformaldehyde solution
(4% w/v). As observed in Figure 3A, the pancreas/bodyweight ratio of
the pancreas of STC2-/- mice was greater than that from WT mice
(0.0069  0.0003 ratio in STC2-/- mice versus 0.0052  0.0003
ratio in WT mice; n = 6, P < 0.001).
The histological analysis revealed that STC2-/- mice fed with the
RP diet presented lesser number of pancreatic islets but of a greater
size than WT mice (Fig. 3B), which is consistent with the observation
that the pancreatic islets of STC2-/- mice presented a slightly higher
number of cells (non-significant), and of bigger size than the cells of
WT mice (See Fig. 3B, bottom right-hand graph), which might explain
how STC2-/- mice under RP diet can compensate the blood glucose
concentration (see Fig. 2). Interestingly, WT mice react to hyper-
caloric diet (BP diet) by increasing the size of the islets, which is likely
due to the greater number of cells that are also bigger in size than in
mice feed with RP (See Fig. 3B, black bars in the top right-hand graph
and black bars in the bottom graphs). In contrast, STC2-/- mice sub-
jected to hypercaloric BP diet were unable of reorganizing the pan-
creas tissue with the same efficiency than WT mice did in response to
hypercaloric BP diet (See Fig. 3B grey-dotted bars). Although the
number of the pancreas islets increased significantly (Fig. 3B, grey-
dotted bars in the top left-hand graph), the islet size was not modify
in response to BP diet (Fig. 3, grey-dotted bars in top-rich hand
graph); furthermore, neither changes in the number of cells/islet nor
cell size in response to BP was observed in the STC2-/- mice (See
Fig. 3B bottom graphs), which might explain that STC2-/- mice were
unable to keep the glycaemia under control as commented above and
it is described in the Figure 2.
As demonstrated in Figure 4, the histological study revealed cyto-
logical differences in the islet components of each study group feed
with both types of diets, although more evident in individuals under-
going BP. The islet cells in the WT mice showed a cytoplasm occu-
pied by large vacuoles which might consist of intracellular oil deposit
as result of hypercaloric diet as previously reported by others [33],
sometimes a single vacuole that displaces the nucleus (compares the
different images shown in the Fig. 4A). In contrast, KO individuals
showed cells with small and larger vacuoles, giving the cytoplasm a
foamy appearance (Fig. 4A-image 4). It is noteworthy that in the exo-
crine portion in some KO animals subjected to BP diet, there was
evidence of non-purulent pancreatitis, accompanied in some cases of
cellular necrosis (see asterisks in Fig. 4B). Finally, no nuclear
changes were observed in any group.
In addition, a very positive STC2 expression has been previously
describe within the alpha-islet pancreatic cells; thus, authors inferred
a possible glucagon regulation [4]. Here, using a primary antigluca-
gon antibody, and subsequently, a FITC-conjugated specific sec-
ondary antibody, we have observed a more evident positive stain in
the pancreas sections of STC2-/- mice fed with BP, respect to those
sections obtained from WT mice fed under the same regimes (see
arrowheads in Fig. 5). Interestingly, pancreatic tissue alteration was
also demonstrated by comparing the erythrocyte infiltration observed
in the STC2-/- slices respect to the WT ones (see asterisks in Fig. 5,
that point to haemoglobin autofluorescence).
Finally, glucagon altered production was also confirmed in Fig-
ure 6, where using a commercial ELISA test against glucagon, we
were able to detect enhanced circulating glucagon levels in the
STC2-/- mice fed with BP. Thus, hyperglycaemic condition due to the
lack of STC2 expression results from a combination of deregulating
insulin and glucagon secretion.
Fig. 4 Histological images of Langerhans islets and exocrine pancreas
of the study mice. Histological sections were obtained and observed
as described in Materials and Methods section. (A) WT, regular diet
(1), WT, hypercaloric diet (2), KO, regular diet (3), KO, hypercaloric
diet (4) (Scale bar=50 lm). (B) KO, hypercaloric diet. It is shown
necrotic phenomena (*) including inflammatory cells (arrows) (Scale
bar=100 lm).
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Discussion
DM2 is a global pandemic disease, affecting up to 415 million of
patients according to the international diabetes foundation (www.
IDF). Although there are no experimental data available yet, scientists
and physicians agree with the fact that the lifestyle adopted by Wes-
tern societies might contribute to worsening the genetic predisposi-
tion of suffering this disease [26, 34]. The nowadays lifestyle is
characterized by an unhealthy diet combined with an elevated rates of
sedentary lifestyle and long working periods full of stressful situations
[35, 36]. Regarding the latest, in the literature few candidate genes
have been pointed for predisposing to suffer DM2 [37–40], and those
reported are mainly linked with the glucose and insulin metabolism.
Besides to the prevention campaigns, mainly consisting in changing
the lifestyle and diet, an early diagnosis would be relevant for tackling
the possible collateral damages evoked by high circulating glucose
[41]. In the present study, some of these previous observations were
reproduced in the way that a large number of DM2 included in the
present study are also obese, which is worsening the regulation of
glycaemia as reflected by the fact that most of them presented ele-
vated glycosylated haemoglobin, despite being under antiglycaemic
medication (some of them even required the prescription of two dif-
ferent types of antiglycaemic drugs).
Fig. 5 Glucagon immunostaining in WT and STC2-/- mice. Pancreatic samples were obtained as described in the Materials and Methods section,
upon which non-specific binding site were blocked. Incubation with the primary antiglucagon antibody (1:250 in TBS) was performed overnight at
4°C. Upon washing with TBS, adequate FITC-conjugated secondary antibody was used for 30 min. at room temperature; after which, the samples
were observed under an inverter epifluorescence microscope. Images were acquired using an excitation wavelength of 450 nm, to avoid excitation
and emission overlapping, and are representative of eight to 10 mice preparations. Arrowheads represent positive glucagon staining, then alpha cells
or secreted glucagon; meanwhile, asterisk indicates erythrocyte autofluorescence (Scale bar = 50 lm).
Fig. 6 Circulating glucagon in WT and STC2-/- mice feed with BP. Blood
sample were drawn as described in Materials and Methods section.
Upon plasma isolation, it was loaded in a 98-well ELISA test against
glucagon. Histogram represents the average of two independent experi-
ments using STC2 KO (4) and WT (6) fed with BP. ***represents
P < 0.05 according to the Student’s t-test.
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In addition, STCs have emerged as possible markers of dia-
betes appearance and progression, as it was initially described that
STC2 colocalized with glucagon in the alpha cells of the pancreas
islets [4] and, later on, these authors demonstrated that contrary
to healthy individuals, no correlation was found between circulating
insulin and STC2 concentrations in DM2 patients [42]. Using an
experimental chemical pancreas injury model (consisting in the
administration of cerulein), it has been reported that STC2 is over-
expressed and might be acting as a protective mechanism [8]. In
addition, STC1 was proposed to contribute in the regulation of glu-
cose in both rats and fish by affecting to the kidney gluconeogen-
esis pathway [13]; meanwhile, the same research group has also
proposed that STC2 would impair glucose oxidation in the liver
and muscle (Goncalves AS, Rossetti CL, Fontella L, Severo L,
Kucharski LC, Shein V, Da Silva RSM personal communication).
Furthermore, these authors have also proposed that STC2 might
regulate the glycogen synthesis from alanine in the liver (Rossetti
CL, Master dissertation). However, more experimental evidence is
needed for establishing STCs as solid markers of diabetes mellitus.
In the present study, we have used the C57BL/6J mice linage, as
previously done by others in similar glucose tolerance investiga-
tions. These previous studies described that male mice of this
linage were able to keep the glucose under strict regulation inde-
pendently of the age, as demonstrated by performing glucose tol-
erance test using both oral and intraperitoneal pathways for
administering glucose [25]. In the present, we reproduced this
observation as no significant changes are observed between WT
C57BL/6J mice fed either with regular pellet (Teklad 2014) or
breeding pellet (Teklad 2018). Furthermore, these authors demon-
strated an increased insulin production by the pancreas in
response to glucose overload and showed a possible organ adap-
tive response by evoking pancreas islet enlargement [25]. A simi-
lar pancreas plasticity was also demonstrated in rats [43].
Similarly, under our experimental conditions, WT mice were ade-
quately adapted to hypercaloric diet by evoking the enlargement of
the pancreas tissue, but particularly by increasing the size of the
pancreas islets and showing cells filled of big vacuoles which con-
sist of oil deposit as previously described [33]. Contrary, previous
manuscripts reported pancreatic damage derived from high-fat diet
administration which results in fat accumulation in the pancreas
and other organs. In other hand, hypercaloric diet also evoked big
micro- and macrolipid deposits [25], but also we observed islet
cell hyperplasia in response to the hypercaloric diet, as confirmed
by the fact that the pancreas islets presented more cells of bigger
size. In addition, it has been previously observed by others that b-
cells are capable of proliferate under high insulin demanding con-
ditions, due to activation of the endoplasmic reticulum stress
adaptive mechanism known as unfolding protein response (UPR)
[25, 44]. In this sense, STC2 was able to protect the pancreas tis-
sue from the reticular stress evoked by cerulein administration; it
is noteworthy that STC2 has been reported as part of the UPR in
response to oxidative stress and hypoxia in pancreatic tissue and
neurones [8, 9], downstream of PERK, while enhanced expression
of STC1 was reported only in response to oxidative stress in tis-
sues like lung and kidneys [45, 46].
On the other hand, STC2-/- mice fed with the hypercaloric diet were
unable to regulate blood glycaemia. Contrary to what it would be
expected, STC2-/- mice fed with regular pellet (Teklad 2014) presented
a similar glycaemia than WT mice. A possible explanation for this dis-
crepancy relies in the fact that STC2-/- mice presented less number of
islet in the pancreas but of significant bigger size and contain greater
cells, without qualitative differences with the others fed with regular
diet. In addition, inflammatory areas and necrotic events have been
shown due to stress induced by the diet [47]. Then, perhaps these tis-
sue morphologic alterations evoke that STC2-/- mice are capable of
compensating insulin production under a regular diet, but the pancre-
atic alterations resulted insufficient for protecting against the higher
insulin demanding and stressing situation evoked by a hypercaloric
diet. In fact, we have observed altered glucose oral test but not insulin
resistance in STC2-/- fed with BP, but not in WT mice fed with the same
regime. Similarly, STC2 silencing resulted in an elevated intrapancreatic
stain of glucagon, and in an enhanced circulating glucagon concentra-
tion. As mention above UPR would be in the background of the adapta-
tion mechanism to highly demanding diets, and it has been reported
that STC2 would allow cells to survive during UPR [25, 44, 48], then
facilitating cell overcome a stressful environmental conditions and to
survive to deadly signalling, and even promoting cell proliferation such
as occurs in certain types of cancer [49, 50]. The latest would explain
why cells belonging to pancreas islet of WT mice are able to proliferate
under the stressing stimulus of a hypercaloric diet, while STC2-/- mice
are not capable of adapting to this demanding situation, and subse-
quently, inflammatory and necrotic phenomena are frequent [47]. How-
ever, other possible explanation of the enhanced glucagon secretion
was observed in the STC2-/- mice relays in the negative regulatory func-
tion of STC2 over the calcium entry mechanism shown by Zeiger et al.
[7]; hence, lack of STC2 might lead to excessive calcium concentration
in the alpha-islet cells, and subsequently, in a bigger glucagon process-
ing and secretion, so enhancing post-prandial glycaemia. The latest
might explain that patients who required GLP-1 analogues presented
the lowest levels of STC2, although statistical significance could not be
stablished with in the analysed population.
The results presented here, together with the fact that STC2-/-
mice present neonatal and post-natal oversize [32], lead us to con-
clude that an alteration in STC2 expression may predispose to suffer
DM2 within the obese population. Summarizing, our result would
indicate that STCs and particularly STC2 are a suitable marker of DM2
appearance and progression, and might be a linking protein between
obesity and DM2.
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